20
NEUROCOGNITIVE DIGITAL BIOMARKES
NEUROCOGNITIVE DIGITAL BIOMARKES
_Mr. GREEN IS NOT ALONE
• Cases expected to triple in
2050
• Every 3 seconds someone in
the world develops dementia
+65 DIES WITH DEMENTIA
_Mr. GREEN IS NOT ALONE
+65 DIES WITH DEMENTIA
75% UNDIAGNOSEDCASES WORLDWIDE
• Cases expected to triple in
2050
• Every 3 seconds someone in
the world develops dementia
_STAGES OFALZHEIMER’S
• The progression of the disease
can be slowed by acting
quickly
MCI
Mild AD
Moderate/ Severe AD
_STAGES OFALZHEIMER’S
• The costs of AD increase with
the pathology progression
HEALTHYMILD COGNITIVE
IMPAIRMENT MILD MODERATE
U$3K U$6.5K U$16K U$29K
ALZHEIMER’S DISEASE
SEVERE
U$44K
_STAGES OFALZHEIMER’S
• The costs of AD increase with
the pathology progression
HEALTHYMILD COGNITIVE
IMPAIRMENT MILD MODERATE
U$3K U$6.5K U$16K U$29K
ALZHEIMER’S DISEASE
SEVERE
U$44KEARLY DIAGNOSE
_EARLY DETECTION
• Symptoms can be postponed
of even controlled if dementia
is diagnosed in the early stages
_EARLY DETECTION
• Symptoms must be identified
in Primary Care
PRE-SYMPTOMATIC
MCI
AD
PRIMARY CARE
_EARLY DETECTION
Quick Neurocognitive Evaluations:
• Low Sensibility
• Low Specificity
PRIMARY CARE
ACCURATELOW ACC.
SPECIALIZED PHYCISIANS
PRIMARY CARENEURO.
EVALUATION
_EARLY DETECTION
Neurocognitive Batteries:
• Up to 6 hours
• Medium-High Sensibility
• Low Specificity
• Results are subjective
NUEROCOGNITIVEBATTERY
PRIMARY CARENEURO.
EVALUATION
PRIMARY CARE
ACCURATELOW ACC.
SPECIALIZED PHYCISIANS
_EARLY DETECTION
Tools for early detection are:
• Invasive
• Costly
• Time consuming
• Complex
NUEROCOGNITIVEBATTERY
BIOMARKERS
NEUROIMAGES
PRIMARY CARENEURO.
EVALUATION
PRIMARY CARE
ACCURATELOW ACC.
SPECIALIZED PHYCISIANS
_VIEWMIND
A quick and simple tool for the
early detection of Alzheimer’s and
other dementias NUEROCOGNITIVEBATTERY
BIOMARKERS
NEUROIMAGES
PRIMARY CARENEURO.
EVALUATION
PRIMARY CARE
ACCURATELOW ACC.
SPECIALIZED PHYCISIANS
_THE PRODUCT
SHORT TERM MEMORY BINDING
(4 MIN)
READING TASK(3 MIN)
LABYRINTH(4 MIN)
N-BACK TEST(5 MIN)
• 10 minutes Eye-Tracking test
• Non-invasive, automatized
and standardized
• Series of tests to quantify
cognitive functions
• Patented algorithms
• Clinically validated
CONTROL
_READING BEHABIOUR
CONTROL ALZHEIMER’S DISEASE
_READING BEHABIOUR
_THE PRODUCT
• 10 minutes Eye-Tracking test
• Non-invasive, automatized
and standardized
• Series of tests to quantify
cognitive functions
• Patented algorithms
• Clinically validated
PRE-SYMPTOMATIC
MCI
AD
_THE PRODUCT
• 10 minutes Eye-Tracking test
• Non-invasive automatized
and standardized
• Series of tests to quantify
cognitive functions
• Patented algorithms
• Clinically validated
PRE-SYMPTOMATIC
MCI
AD
98% ACCURACY
_THE PRODUCT
• 10 minutes Eye-Tracking test
• Non-invasive automatized
and standardized
• Series of tests to quantify
cognitive functions
• Patented algorithms
• Clinically validated
PRE-SYMPTOMATIC
MCI
AD
93% ACCURACY15 YEARS
98% ACCURACY
_PROGRAM FOR DEMENTIAPREVENTIO
• Free program for the
prevention of Dementia
• Medicaments for prevention
• Non-drug assistance for
prevention
